Searchable abstracts of presentations at key conferences in endocrinology

ea0077p118 | Thyroid | SFEBES2021

Cost-effectiveness analysis of liothyronine for the management of treatment unresponsive hypothyroidism based on latest evidence

Heald Adrian , Skiadas Konstantinos , Fitzsimmons Deborah , Anderson Pippa , Hughes Dyfrig

Introduction: Between 5-10% of patients with hypothyroidism treated with levothyroxine (T4) continue to experience profound symptoms, despite achieving free T4/thyroid stimulating hormone concentrations within reference range. Liothyronine is sometimes added to levothyroxine, but its use is controversial due to uncertainties in clinical/cost effectiveness.Methods: An economic model was developed to estimate the incremental cost per quality-adjusted life ...

ea0065p412 | Thyroid | SFEBES2019

Health utility of people with treatment-resistant hypothyroidism as measured with the EQ-5D-5L quality of life questionnaire

Hughes Dyfrig , Townson Julia , Owen-Jones Eleri , Playle Rebecca , Khan Inamullah , Kochhar Rupinder , Naseem Asma , Heald Adrian

Background: Primary hypothyroidism affects about 3% of the general population (5.1% women and 0.9% men). The majority of people are treated adequately with levothyroxine. However about 5–10% of hypothyroid patients (representing between 75 000 and 150 000 adults in the UK) continue to experience profound and sometimes disabling symptoms, such as fatigue/depression/impaired cognition, in spite of being adequately replaced biochemically. Before any trial of alternatives to ...

ea0033p59 | (1) | BSPED2013

Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial

Blair Jo , Awoyale Lola , Thornborough Keith , Peak Matthew , Didi Mohammed , Bedson Emma , Hughes Dyfrig , Ridyard Colin , Tat Tri , Gregory John

Background: Delivery of clinical trials to time and target is critical for studies to be financially viable and relevant. Feasibility studies are informative. However, protocol acceptability and recruitment rates can only be accurately ascertained once a study is open.The SCIPI study (SubCutaneous Insulin: Pumps or Injections?), randomises patients to treatment with multiple daily injections (MDI) or pumps at diagnosis of type I diabetes (TID). A consent...